Evofem Biosciences (EVFM) Tops Q2 EPS by 14c

Evofem Biosciences (NASDAQ: EVFM) reported Q2 EPS of ($0.27), $0.14 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $1.86 million versus the consensus estimate of $2.92 million.

For earnings history and earnings-related data on Evofem Biosciences (EVFM) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• NVE Corporation names new CEO and expands board to seven members
• Pfizer lung cancer drug misses survival goal in Phase 3 trial